Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 11, 2026
Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge?
View original at finance.yahoo.com“For AstraZeneca, the latest twelve month Free Cash Flow (FCF) is about US$9.49b.”
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
AstraZeneca has a valuation score of 3 out of 6
60% confidenceThe DCF model arrives at an estimated intrinsic value of US$238.68 per share for AstraZeneca
60% confidenceAstraZeneca's DCF analysis suggests the stock is undervalued by 36.2%
60% confidence
Data points we hold from this source
| AstraZeneca AB · stock return 30day | 5.2 percent |
| AstraZeneca AB · stock return 1year | 54.8 percent |
| AstraZeneca AB · free cash flow | 9.49 USD |
| AstraZeneca AB · stock return ytd | 12.1 percent |
| AstraZeneca AB · projected free cash flow | 20.16 USD |
| AstraZeneca AB · valuation score | 3 out_of_6 |
| AstraZeneca AB · intrinsic value dcf | 238.68 USD |
| AstraZeneca AB · stock return 7day | -0.6 percent |
